Venture Life Group Jumps as Revenue Surges, Fueled by UK Growth

The Venture Life Group (LON: VLG) share price jumped more than 2% on Monday after the company posted a strong trading update for the year ended December 31, 2025, showcasing significant revenue growth driven by its branded consumer healthcare business.

The company's shift to a pure-play branded strategy, coupled with increased investment in advertising and new product development, appears to be paying dividends.

Revenue reached £35.1 million, a 32.0% increase compared to the previous year (£26.6 million). On a proforma basis, assuming acquisitions were in place for the entirety of the prior year, revenue increased by 11.1%, comprising 0.9% from price increases and 10.2% from volume sold.

Power Brands, including Balance Activ, Lift/Glucogel, Earol, and Health & Her/Him, collectively grew 14.9% to £33.1 million. The UK market proved particularly robust, with a 20.7% revenue increase to £25.7 million, fueled by increased A&P spending.

The international business experienced an 8.7% decline to £9.4 million, attributed to order timing from partners and temporary disruptions in Scandinavia. The company is actively working to stabilize and grow the international business through key strategic partnerships.

Venture Life is focused on growing key strategic partnerships with larger counterparties in key markets, which will bring more stability and predictability to international revenues and profitability. As part of this focus, the decision was taken to close the Spanish office that managed these international partners and incorporate this function within the UK-based commercial team.

Investment in new product development (NPD) is a key priority. This focus, under the leadership of Chief Innovation Officer Kate Bache, is fundamental to brand success and value growth. The company is also investing in integrated digital technologies, including a new Microsoft Dynamics 365 ERP system, to drive efficiencies and support its data-driven strategy.

The company continues to actively pursue immediately earnings-enhancing M&A opportunities and is actively working on a number of potential targets within complementary sectors across women's health, men's health, energy management, and hormonal health.

As of December 31, 2025, Venture Life held a net cash position of £34.4 million. The company's share buyback program remains ongoing, with £1.1 million returned to shareholders through the acquisition of approximately 1.7 million ordinary shares.

CEO Jerry Randall commented, “Our decision to meaningfully increase A&P spend in the UK during 2025 has been vindicated by the revenue growth seen across the Power Brands, which are well ahead of sector norms… We have entered 2026 with great momentum and with a reshaped, focused business setup for our future aspirations, as well as being very active in pursuing the right M&A opportunities to leverage our enhanced capabilities and resources.”